Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Liminal BioSciences Inc. LMNL
$6.83
+$0.06 (0.89%)
На 18:02, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
21002532.00000000
-
week52high
7.06
-
week52low
3.10
-
Revenue
401000
-
P/E TTM
98
-
Beta
30.72175400
-
EPS
-6.73000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 10:59
Описание компании
Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company's lead product candidate is fezagepras (PBI-4050), which has been completed Phase I clinical trial for the treatment of idiopathic pulmonary, liver, cardiac, or skin fibrosis with fezagepras or related derivatives and respiratory diseases. It is also developing antagonist candidate programs, including G-protein coupled receptor 84 and Oxo-eicosanoid receptor 1, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Neutral | Buy | 24 июн 2021 г. |
| Piper Sandler | Neutral | Overweight | 02 июн 2021 г. |
| HC Wainwright & Co. | Buy | 18 февр 2021 г. | |
| Piper Sandler | Overweight | 21 дек 2020 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Liminal BioSciences to Present at BIO CEO & Investor Conference
PRNewsWire
19 янв 2023 г. в 16:38
LAVAL, QC and CAMBRIDGE, England , Jan. 19, 2023 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced that Bruce Pritchard, Chief Executive Officer at Liminal BioSciences is scheduled to present a company overview on Tuesday February 7, 2023 at 10:30am (ET) during the BIO CEO & Investor Conference taking place at the New York Marriott Marquis on February 6-9, 2023. The Company will be available for meetings with conference attendees.
Liminal Biosciences (LMNL) Q3 2022 Earnings Call Transcript
Seeking Alpha
13 ноя 2022 г. в 22:17
Liminal Biosciences (NASDAQ:LMNL ) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Shrinal Inamdar - Investor Relations Bruce Pritchard - Chief Executive Officer Nicole Rusaw - Chief Financial Officer Operator Good day and welcome to the Liminal Biosciences Third Quarter 2022 Results conference call. At this time, I would like to turn the call over to Shrinal.
Liminal BioSciences Inc. (LMNL) CEO Bruce Pritchard on Q1 2022 Results - Earnings Call Transcript
Seeking Alpha
13 мая 2022 г. в 15:22
Liminal BioSciences Inc. (NASDAQ:LMNL ) Q1 2022 Earnings Conference Call May 11, 2022 8:30 AM ET Company Participants Shrinal Inamdar - Investor Relations & Communications Manager Bruce Pritchard - Chief Executive Officer Nicole Rusaw - Interim Chief Financial Officer Conference Call Participants Ed Arce - H.C. Wainwright Operator Good day and welcome to the Liminal BioSciences, Inc. First Quarter 2022 Results Conference Call.
Liminal Biosciences to Present at Upcoming Investor Conferences
PRNewsWire
09 мая 2022 г. в 08:30
LAVAL, QC, and CAMBRIDGE, England , May 9, 2022 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced that Bruce Pritchard, Chief Executive Officer at Liminal BioSciences is scheduled to present a company overview at the following upcoming investor conferences: H.C. Wainwright Global Investment Conference on Tuesday 24th May at 2:30-3:00 PM (EDT).